A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Plus Motolimod and With Cetuximab Plus Motolimod Plus Nivolumab
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Motolimod (Primary) ; Cetuximab; Nivolumab
- Indications Head and neck cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors VentiRx Pharmaceuticals
- 23 Oct 2017 Results (n=14) assessing the effect of neoadjuvant cetuximab plus motolimod, published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 06 Jan 2016 New drug 'Nivolumab' has been added in the study and also 1 treatment arm has been added as reported by ClinicalTrials.gov record.
- 06 Jan 2016 Planned number of patients changed from 15 to 24 as reported by ClinicalTrials.gov record.